Shaanxi Meibang Pharmaceutical Group Co., Ltd. (SHA:605033)
21.61
+0.38 (1.79%)
Feb 6, 2026, 3:00 PM CST
SHA:605033 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 296.76 | 267.86 | 481.17 | 318.25 | 254.39 | 199.41 |
Short-Term Investments | - | - | - | 1.5 | - | - |
Trading Asset Securities | 346.5 | 388.47 | - | 79.93 | 148 | - |
Cash & Short-Term Investments | 643.27 | 656.33 | 481.17 | 399.68 | 402.39 | 199.41 |
Cash Growth | 22.95% | 36.40% | 20.39% | -0.67% | 101.79% | -9.25% |
Accounts Receivable | 108.77 | 77.16 | 148.68 | 189.08 | 92.49 | 25.84 |
Other Receivables | 2 | 12.29 | 10.52 | 35.69 | 2.04 | 2.4 |
Receivables | 110.77 | 89.45 | 159.2 | 224.77 | 94.53 | 28.24 |
Inventory | 176.69 | 264.71 | 353.7 | 457.29 | 559.56 | 277.97 |
Prepaid Expenses | - | - | - | 14.09 | - | - |
Other Current Assets | 124.81 | 86.22 | 77.73 | 92.58 | 136.3 | 100.55 |
Total Current Assets | 1,056 | 1,097 | 1,072 | 1,188 | 1,193 | 606.16 |
Property, Plant & Equipment | 695.22 | 613.67 | 457.07 | 185.84 | 115.72 | 96.13 |
Other Intangible Assets | 115.68 | 118.48 | 83.23 | 12.27 | 7.7 | 7.94 |
Long-Term Deferred Tax Assets | 16.61 | 15.7 | 16.43 | 12.42 | 4.26 | 3.31 |
Long-Term Deferred Charges | 0.61 | 0.54 | 0.42 | 0.76 | 0.97 | - |
Other Long-Term Assets | 21.38 | 16.93 | 63.05 | 160.79 | 141.94 | 72.33 |
Total Assets | 1,905 | 1,862 | 1,692 | 1,560 | 1,463 | 785.87 |
Accounts Payable | 167.72 | 305.84 | 171.77 | 102.68 | 130.52 | 84.03 |
Accrued Expenses | 23.51 | 48.13 | 50.06 | 75.87 | 44.23 | 20.25 |
Short-Term Debt | 10 | - | 1 | - | 27.05 | - |
Current Portion of Long-Term Debt | 3 | 1.08 | - | - | - | - |
Current Income Taxes Payable | 1.49 | 0.44 | 1.77 | 2.85 | 5.55 | 1 |
Current Unearned Revenue | 296.11 | 252.07 | 227.97 | 151.4 | 219.24 | 195.5 |
Other Current Liabilities | 29.05 | 8.7 | 8.34 | 36.93 | 10.48 | 9.94 |
Total Current Liabilities | 530.88 | 616.26 | 460.91 | 369.72 | 437.07 | 310.73 |
Long-Term Debt | 137 | 72 | - | - | - | - |
Long-Term Unearned Revenue | 3.06 | 3.25 | 1.2 | 0.78 | 0.87 | - |
Long-Term Deferred Tax Liabilities | 4.77 | 4.61 | 4.78 | 5.63 | 5.42 | 4.33 |
Other Long-Term Liabilities | 81.98 | 41.26 | 110.96 | 98.02 | 53.08 | 21.44 |
Total Liabilities | 757.69 | 737.37 | 577.84 | 474.14 | 496.43 | 336.5 |
Common Stock | 135.2 | 135.2 | 135.2 | 137.79 | 135.2 | 101.4 |
Additional Paid-In Capital | 459.37 | 459.37 | 459.37 | 482.34 | 459.37 | 101.33 |
Retained Earnings | 552.77 | 530.09 | 519.6 | 491.78 | 372.38 | 246.64 |
Treasury Stock | - | - | - | -25.57 | - | - |
Shareholders' Equity | 1,147 | 1,125 | 1,114 | 1,086 | 966.95 | 449.37 |
Total Liabilities & Equity | 1,905 | 1,862 | 1,692 | 1,560 | 1,463 | 785.87 |
Total Debt | 150 | 73.08 | 1 | - | 27.05 | - |
Net Cash (Debt) | 493.27 | 583.25 | 480.17 | 399.68 | 375.34 | 199.41 |
Net Cash Growth | 9.57% | 21.47% | 20.14% | 6.49% | 88.22% | 10.97% |
Net Cash Per Share | 3.64 | 4.27 | 3.59 | 2.95 | 3.40 | 1.98 |
Filing Date Shares Outstanding | 135.2 | 135.2 | 135.2 | 137.79 | 135.2 | 101.4 |
Total Common Shares Outstanding | 135.2 | 135.2 | 135.2 | 137.79 | 135.2 | 101.4 |
Working Capital | 524.65 | 480.45 | 610.89 | 818.69 | 755.71 | 295.43 |
Book Value Per Share | 8.49 | 8.32 | 8.24 | 7.88 | 7.15 | 4.43 |
Tangible Book Value | 1,032 | 1,006 | 1,031 | 1,074 | 959.25 | 441.42 |
Tangible Book Value Per Share | 7.63 | 7.44 | 7.63 | 7.79 | 7.10 | 4.35 |
Buildings | - | 155.85 | 70.81 | 68.09 | 62.58 | 56.78 |
Machinery | - | 201.85 | 151.47 | 146.71 | 101.66 | 76.73 |
Construction In Progress | - | 364.64 | 325.93 | 44.37 | 11.93 | 10.93 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.